Stay updated with breaking news from Mark Schoenberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target cut by Oppenheimer from $34.00 to $32.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $54.00 target price on shares of UroGen Pharma […]
There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location RFS Was 100% in Patients who Received Maintenance...
60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent ...
04.05.2024 - UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using ... Seite 1
New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates at 12 months ...